Preclinical Program News Today

During the Coronavirus Crisis is the man who at least on a personal level for my family made that possible. I mean, how many people do you know said they would not get vaccinated against the coronavirus unless and until dr. Fauci got vaccinated . Unless and until they heard from dr. Fauci personally that its time, that its safe. That this is how were going to beat this thing. How crucial has the Publics Trust in this one scientist been . Since the start of this global and National Nightmare . It...

Fauci got vaccinated . Unless and until they heard from dr. Fauci personally that its time, that its safe. That this is how were going to beat this thing. How crucial has the Publics Trust in this one scientist been . Since the start of this global and National Nightmare . It is an unprecedented thing in american history. And dr. Anthony fauci joins us tonight for the interview. Dr. Fauci, i feel like we have a lot of catching up to do. Ive been trying to get an interview with you on the show si...

15.12.2021 - Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Exicure, Inc. (NASDAQ: XCUR) securities between March 11, 2021 and November 15, 2021, ...

Share this article Share this article PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ -- Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficac...

Vancouver, BC –  January 25, 2021 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to provide a corporate update on recent advancements of its vaccine platforms, viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. The Company plans to seek a compassionate use approval in th...